CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $969,122 | -17.7% | 21,351 | +1.7% | 0.01% | -20.0% |
Q2 2023 | $1,178,154 | +20.9% | 20,986 | -2.6% | 0.01% | +11.1% |
Q1 2023 | $974,752 | +14.7% | 21,551 | +3.1% | 0.01% | +12.5% |
Q4 2022 | $850,032 | -35.0% | 20,911 | +4.6% | 0.01% | -42.9% |
Q3 2022 | $1,307,000 | +8.2% | 19,996 | +0.6% | 0.01% | +16.7% |
Q2 2022 | $1,208,000 | +16.3% | 19,876 | +20.1% | 0.01% | +50.0% |
Q1 2022 | $1,039,000 | -16.4% | 16,549 | +0.9% | 0.01% | -11.1% |
Q4 2021 | $1,243,000 | -32.7% | 16,407 | -0.6% | 0.01% | -40.0% |
Q3 2021 | $1,848,000 | -30.4% | 16,511 | +0.7% | 0.02% | -31.8% |
Q2 2021 | $2,655,000 | +26.6% | 16,403 | -4.7% | 0.02% | +22.2% |
Q1 2021 | $2,097,000 | -10.3% | 17,213 | +12.8% | 0.02% | -14.3% |
Q4 2020 | $2,337,000 | +80.6% | 15,262 | -1.4% | 0.02% | +61.5% |
Q3 2020 | $1,294,000 | +97.3% | 15,476 | +73.4% | 0.01% | +44.4% |
Q2 2020 | $656,000 | +119.4% | 8,927 | +26.6% | 0.01% | +80.0% |
Q1 2020 | $299,000 | – | 7,052 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |